Buyers eye Relypsa and its hyperkalemia drug

ZS Pharma

While pharma M&A action has slowed, it is not dead. After AstraZeneca ($AZN) last year agreed to pay $2.7 billion for ZS Pharma ($ZSPH) it stoked interest in new treatments for the blood disorder hyperkalemia, and Relypsa ($RLYP) has one already approved, Veltassa. That, Reuters says, has drawn buyout interest, leading the Redwood City, CA-based biotech to hire an investment bank to check out its offers. Relypsa isn't commenting but the news service says several companies that had bid on ZS, including Actelion, are eyeing Relypsa. More from FierceBiotech


Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.